Assessing Functional Similarity of Biosimilar ABP 654 and Ustekinumab in Samples from Patients with Crohn’s Disease
These studies demonstrated similar inhibition of IL-23 and IL-12 function by ABP 654 and ustekinumab RP in both healthy and CD PBMCs. Overall, these assays support the conclusion that ABP 654 and ustekinumab RP are functionally similar, thereby contributing to the TOE supporting a demonstration of biosimilarity.
Authors
- Helen Y. Wong (ORCID: https://orcid.org/0000-0002-5695-1580)
- Ian N. Foltz
- Kevin Gaida
- Jennifer Liu (ORCID: https://orcid.org/0000-0002-3574-9586)
- Michael Ng
- Marijana Busch
Institutions
- Amgen (United States) (US)
- Amgen (Canada) (CA)
Publication Details
- Journal
- Journal of Inflammation Research
- Published
- 2024-12-01
- DOI
- https://doi.org/10.2147/jir.s478529
- Citations
- 1
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.24
Funders
- Amgen